Product Description
Choline fenofibrate is a newly developed choline salt of fenofibric acid, which is more hydrophilic than fenofibrate. Choline fenofibrate delayed release 135 mg is as safe and effective as 160 mg of micronized fenofibrate in Indian patients with mixed dyslipidemia. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743387/)
Mechanisms of Action: PPAR-a Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Chile | Dominican Republic | Ecuador | India | Korea | Russia | Singapore | Switzerland | Taiwan | Thailand | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Dyslipidemia|Type 2 Diabetes|Atherosclerosis|Carotid Artery Diseases
Phase 3: Coronary Artery Disease|Myocardial Ischemia|Hypertriglyceridemia|Dyslipidemia|Atherosclerosis
Phase 2: Multiple Myeloma|Dyslipidemia|Macular Edema|Medulloblastoma|Ependymoma|Alcoholism|COVID-19
Phase 1: Healthy Volunteers|Tobacco Use Disorder|Hypertension|Other|Hyperlipidemia|Hypertriglyceridemia|Dyslipidemia|Hypercholesterolemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MEMMAT | P2 |
Recruiting |
Medulloblastoma|Ependymoma |
2030-04-01 |
|
| B-2111-720-003 | P4 |
Recruiting |
Type 2 Diabetes|Carotid Artery Diseases|Dyslipidemia|Atherosclerosis |
2025-12-31 |
|
| FERMIN | P2 |
Completed |
COVID-19 |
2022-03-30 |
|
| Pro00079289 | P4 |
Completed |
Type 2 Diabetes |
2020-03-04 |